Med hensyn til tyktarmskræft er Xeloda anvendt som enebehandling blevet sammenlignet med kombinationen af 5- FU og folinsyre (et lægemiddel, der øger virkningen af 5- FU) hos 1 987 kræftopererede patienter.
In colon cancer, Xeloda on its own has been compared with the combination of 5-FU and folinic acid (a medicine that enhances the effects of 5-FU) in 1,987 patients who had previously had surgery for their cancer.